$VYNE
VYNE Therapeutics Inc. Stock $vyne

$vyne Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024046244 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$100.0K	$114.0K
YoY Change		-12.28%	-31.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$2.964M	$3.030M
YoY Change		-2.18%	-23.37%
% of Gross Profit
Research & Development		$10.25M	$3.318M
YoY Change		208.86%	-40.17%
% of Gross Profit
Depreciation & Amortization			$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses		$10.25M	$6.348M
YoY Change		61.44%	-33.18%
Operating Profit		-$13.09M	-$6.234M
YoY Change		109.99%	-33.2%
Interest Expense			$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net		$934.0K	$163.0K
YoY Change		473.01%	108.97%
Pretax Income		-$12.16M	-$6.071M
YoY Change		100.25%	-34.4%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$12.16M	-$6.584M
YoY Change		84.64%	-30.39%
Net Earnings / Revenue		-12157.0%	-5775.44%
Basic Earnings Per Share		-$0.29	-$2.01
Diluted Earnings Per Share		-$0.29	-$2.01
COMMON SHARES
Basic Shares Outstanding	14.75M shares	14.75M shares	3.280M shares
Diluted Shares Outstanding		42.59M shares	3.282M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.19M	$15.40M
YoY Change	355.75%	-56.63%
Cash & Equivalents	$16.27M	$15.45M
Short-Term Investments	$53.91M
Other Short-Term Assets	$57.26M	$1.900M
YoY Change	2913.84%	-38.01%
Inventory
Prepaid Expenses
Receivables		$250.0K
Other Receivables		$0.00
Total Short-Term Assets	$73.54M	$17.51M
YoY Change	319.94%	-60.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$122.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.541M	$1.800M
YoY Change	41.17%	-34.19%
Total Long-Term Assets	$2.663M	$1.756M
YoY Change	51.65%	-38.64%
TOTAL ASSETS
Total Short-Term Assets	$73.54M	$17.51M
Total Long-Term Assets	$2.663M	$1.756M
Total Assets	$76.20M	$19.27M
YoY Change	295.48%	-58.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.986M	$700.0K
YoY Change	469.43%	-72.26%
Accrued Expenses	$6.168M	$4.452M
YoY Change	38.54%	105.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.66M	$6.449M
YoY Change	96.33%	-5.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$1.300M
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$1.300M
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.66M	$6.449M
Total Long-Term Liabilities	$0.00	$1.300M
Total Liabilities	$12.66M	$7.762M
YoY Change	63.12%	13.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$719.1M	-$685.1M
YoY Change	4.96%	4.95%
Common Stock	$1.000K	$0.00
YoY Change		-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$63.54M	$11.51M
YoY Change
Total Liabilities & Shareholders Equity	$76.20M	$19.27M
YoY Change	295.48%	-58.93%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$12.16M	-$6.584M
YoY Change	84.64%	-30.39%
Depreciation, Depletion And Amortization		$0.00
YoY Change		-100.0%
Cash From Operating Activities	-$8.510M	-$5.150M
YoY Change	65.24%	-27.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$4.824M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$4.824M	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.000K	-50.00K
YoY Change	-96.0%	92.31%
NET CHANGE
Cash From Operating Activities	-8.510M	-5.150M
Cash From Investing Activities	-4.824M	0.000
Cash From Financing Activities	-2.000K	-50.00K
Net Change In Cash	-13.34M	-5.200M
YoY Change	156.46%	-28.15%
FREE CASH FLOW
Cash From Operating Activities	-$8.510M	-$5.150M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	685 Route 202/206 N, Suite 301
	dei	Trading Symbol TradingSymbol	VYNE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30620000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	54000	usd
CY2024Q3	us-gaap	Assets Assets	76198000	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3986000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6168000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1071000	usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3757789
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-21720000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001566044
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14751433	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16272000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	2663000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1722000	usd
CY2023Q4	us-gaap	Assets Assets	97685000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1659000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4119000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1645000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	115000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1313000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14098888	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14098888	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-719148000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-691336000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	63537000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	88735000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	76198000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97685000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	121000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	417000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	348000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	121000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	31284000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	22774000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13091000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6234000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22426000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	934000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-12157000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6071000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27812000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22264000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.29
CY2024Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.29
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.65
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.65
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-6.66
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-6.66
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.17
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.17
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3282000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3282000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42592000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42592000	shares
	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	92000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	8000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	92000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12065000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27804000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22264000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3000	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	211000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22264000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-35000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2595000	usd
	vyne	Temporary Equity Redeemed Or Called During Period Shares TemporaryEquityRedeemedOrCalledDuringPeriodShares	3000	shares
	vyne	Temporary Equity Redeemed Or Called During Period Value TemporaryEquityRedeemedOrCalledDuringPeriodValue	211000	usd
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	149000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	11505000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	88735000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27812000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2604000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	8000	usd
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	63537000	usd
CY2023Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	17272000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6584000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-46000	usd
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	11505000	usd
CY2024Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	74869000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12157000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-1000	usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	63537000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22264000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2604000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2595000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-1899000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15502000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300000	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25.17pt">Concentration of credit risks</span>Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, marketable securities and accounts receivable. The Company deposits cash and cash equivalents with highly rated financial institutions and, as a matter of policy, limits the amounts of credit exposure to any single financial institution. In addition, all marketable securities carry a high credit rating or are government insured. The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.
CY2022	vyne	Employee Retention Tax Credit EmployeeRetentionTaxCredit	1300000	usd
CY2024Q3	vyne	Disposal Group Milestone Payments Receivable Upon Achievement Of Net Sales DisposalGroupMilestonePaymentsReceivableUponAchievementOfNetSales	450000000.0	usd
	vyne	Milestone Payments Upon Achieving Certain Criteria Exceeding Annual Net Sales MilestonePaymentsUponAchievingCertainCriteriaExceedingAnnualNetSales	100000000.0	usd
	dei	Entity File Number EntityFileNumber	001-38356
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0556
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0556
	dei	Entity Registrant Name EntityRegistrantName	VYNE THERAPEUTICS INC.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
	dei	City Area Code CityAreaCode	800
	dei	Local Phone Number LocalPhoneNumber	775-7936
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	47000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	53913000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	62633000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3303000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2656000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	73535000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	95963000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	122000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	207000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2541000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1515000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12661000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7538000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	99000	usd
CY2024Q3	us-gaap	Other Liabilities OtherLiabilities	0	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	1313000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1412000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	12661000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8950000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14751433	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14751433	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	782650000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	780044000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	34000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	417000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	348000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10248000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3318000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21262000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13284000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2964000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3030000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10022000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9490000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	13212000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	6348000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30867000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	163000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3074000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	706000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12157000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6071000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27793000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21720000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-27793000	usd
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	usd
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-513000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-19000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-544000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12157000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6584000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.85
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.85
CY2024Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0.00
CY2024Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.00
CY2023Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.16
CY2023Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.16
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.00
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.82
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42587000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42587000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3271000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3271000	shares
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6584000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31202000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	156000	usd
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	863000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	734000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	92000	usd
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
	us-gaap	Net Income Loss NetIncomeLoss	-27812000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1587000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1017000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3812000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1552000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-91000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24973000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20204000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	5000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	61100000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	50473000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10627000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	156000	usd
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	usd
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	360000	usd
	vyne	Payments Proceeds From Stock Options Exercised Net PaymentsProceedsFromStockOptionsExercisedNet	-9000	usd
	vyne	Payments Proceeds From Stock Options Exercised Net PaymentsProceedsFromStockOptionsExercisedNet	-65000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-269000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14355000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15473000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30674000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30975000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16319000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16272000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15448000	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	47000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	54000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16319000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15502000	usd
	us-gaap	Stock Issued1 StockIssued1	11000	usd
	us-gaap	Stock Issued1 StockIssued1	29000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	149000	usd
	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF OPERATIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">VYNE Therapeutics Inc. (the "Company") is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, the Company entered into a transaction with Tay Therapeutics Limited, formerly known as In4Derm Limited ("Tay"), providing the Company with exclusive worldwide rights to research, develop and commercialize products containing bromodomain and extra-terminal domain (“BET”) inhibitors for the treatment of any disease, disorder or condition in humans. Through its access to this library of new chemical BET inhibitor compounds, the Company plans to develop product candidates for a diverse set of indications. Based on data generated to date, the Company has chosen to focus its initial efforts for this platform on select therapeutic areas in immuno-inflammatory disease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's lead program is VYN201, a locally administered pan-</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">bromodomain (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">“BD”) BET inhibitor designed as a “soft” drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. In preclinical </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">testing, VYN201 produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models. The Company announced positive results from a Phase 1b trial evaluating VYN201 in nonsegmental vitiligo in October 2023 and initiated a Phase 2b trial in nonsegmental vitiligo in June 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's second program is VYN202, an oral small molecule BD2-selective BET inhibitor. VYN202 has been designed to achieve potential class-leading selectivity and potency (BD2 vs. BD1). By maximizing BD2 selectivity, the Company believes VYN202 has the potential to be a more conveniently administered non-biologic treatment option for both acute control and chronic management of immuno-inflammatory indications, where the damaging effects of unrestricted inflammatory signaling activity are common. The Company initiated a Phase 1a single ascending dose/multiple ascending dose ("SAD"/"MAD") trial of VYN202 in June 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and announced positive data from the SAD portion of the trial in September 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company intends to advance its product candidates through clinical development toward regulatory approval. As part of its strategy to maximize the value of its pipeline, the Company may partner with larger pharmaceutical companies to expand and accelerate the development of its programs and explore therapeutic areas outside of its core focus in immunology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information regarding the sale of the Company's legacy commercial business (the “MST Franchise”) to Journey Medical Corporation ("Journey") in January 2022 and the Company's licensing arrangements with Tay, see "Note 3 - Strategic Agreements." </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as one business segment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reverse stock split and recasting of per-share amounts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, the Company's board of directors approved a 1-for-18 reverse stock split of its outstanding shares of common stock. The reverse stock split was effected on February 10, 2023 at 5:01 p.m. Eastern time. At the effective time, every 18 issued and outstanding shares of the Company's common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each holder of fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company’s transfer agent in an amount equal to such holder’s respective pro rata share of the total net proceeds from the Company’s transfer agent's sale of all fractional shares at the then-prevailing prices on the open market. A proportionate adjustment was also made to the maximum number of shares issuable under the Company’s 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan. The number of authorized shares of the Company's common stock and the par value of each share of common stock remained unchanged. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless noted, all common stock and per share amounts contained in these unaudited condensed consolidated financial statements have been retroactively adjusted to reflect the 1-for-18 reverse stock split.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2023, the Company entered into a Securities Purchase Agreement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the “Securities Purchase Agreement”) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with certain institutional and other accredited investors (collectively, the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “Private Placement”) (i) 10,652,543 shares of the Company’s common stock and (ii) with respect to certain Purchasers, Pre-Funded Warrants to purchase 28,614,437 shares of common stock in lieu thereof (the “Pre-Funded Warrants”). The purchase price per share of common stock was $2.245 per share (the “Stock Purchase Price”) and the purchase price for the Pre-Funded Warrants was the Stock Purchase Price minus $0.0001 per Pre-Funded Warrant. On November 1, 2023, the Company received gross proceeds of $88.2 million from the Private Placement, before deducting fees to the placement agent and offering expenses payable by the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This transaction resulted in $5.5 million of issuance costs and net proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$82.7 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company had cash, cash equivalents, restricted cash and marketable securities of $70.2 million and an accumulated deficit of $719.1 million. The Company had no outstanding debt as of September 30, 2024. For the nine months ended September 30, 2024, the Company incurred a net loss of $27.8 million and used $25.0 million of cash in operations. Other than in connection with its legacy commercial business that was sold in January 2022, the Company has funded its operations primarily through private and public placements of its equity, debt and warrants and through fees, cost reimbursements and payments received from its licensees. The Company has incurred losses and experienced negative operating cash flows since its inception and anticipates that it will continue to incur losses until such a time when its product candidates, if approved, are commercially successful, if at all. The Company will not generate any revenue from any current or future product candidates unless and until it obtains regulatory approval and commercializes such products.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company's available cash, cash equivalents, restricted cash and marketable securities are insufficient to satisfy its liquidity requirements, the Company may need to raise additional capital to fund its operations. No assurance can be given as to whether additional needed financing will be available on terms acceptable to the Company, if at all. If sufficient funds on acceptable terms are not available when needed, the Company may be required to suspend or forego certain planned activities. Failure to manage discretionary spending or raise additional financing, as needed, would adversely impact the Company’s ability to achieve its intended business objectives and have an adverse effect on its results of operations and future prospects. In addition, the amount of proceeds the Company may be able to raise pursuant to its currently effective shelf registration statement on Form S-3 is limited. As of the filing of this Quarterly Report on Form 10-Q, the Company is subject to the general instructions of Form S-3 known as the "baby shelf rules." Under these rules, the amount of funds the Company can raise through primary public offerings of securities in any 12-month period using its registration statement on Form S-3 is limited to one-third of the aggregate market value of the shares of the Company's common stock held by its non-affiliates. Therefore, the Company will be limited in the amount of proceeds it is able to raise by selling shares of common stock using its Form S-3 until such time as the Company's public float exceeds $75.0 million.</span></div>In accordance with Accounting Standards Codification (“ASC”) Subtopic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its unaudited interim condensed consolidated financial statements are issued. The Company believes its existing cash, cash equivalents, restricted cash and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period of at least 12 months from the date of issuance of these unaudited interim condensed consolidated financial statements.
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q3	vyne	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	70200000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-719100000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27800000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt">Use of Estimates</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and reported amounts of income and expenses during the reporting period. Significant items subject to such estimates and assumptions include research and development accruals. Actual results could differ from the Company’s estimates.</span></div>
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	100000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	100000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	400000	usd
CY2024Q3	vyne	Accrued Sales Provisions Current AccruedSalesProvisionsCurrent	2200000	usd
CY2023Q4	vyne	Accrued Sales Provisions Current AccruedSalesProvisionsCurrent	2300000	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	vyne	Proceeds From Employee Retention Tax Credit ProceedsFromEmployeeRetentionTaxCredit	1300000	usd
CY2024Q3	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1300000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16272000	usd
CY2024Q3	us-gaap	Marketable Securities MarketableSecurities	53913000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	70185000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	30620000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	62633000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	93253000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	53913000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	62633000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53880000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	35000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	53913000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62608000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	35000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62633000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	53900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	62600000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q1	vyne	Stock Redeemed Or Called During Period Price As Percentage Of Stated Value StockRedeemedOrCalledDuringPeriodPriceAsPercentageOfStatedValue	1.20
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	27509	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.40
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	5285	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	8339	shares
	vyne	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	2400000	usd
	vyne	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue	0	usd
CY2024Q3	vyne	Number Of Shares Issued For Each Vesting Rsu NumberOfSharesIssuedForEachVestingRSU	1	shares
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	734000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	863000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2604000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2595000	usd
CY2024Q3	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-046244-index-headers.html	Edgar Link	pending
0001628280-24-046244-index.html	Edgar Link	pending
0001628280-24-046244.txt	Edgar Link	pending
0001628280-24-046244-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vyne-20240930.htm	Edgar Link	pending
vyne-20240930.xsd	Edgar Link	pending
vyne-20240930xexx311.htm	Edgar Link	pending
vyne-20240930xexx312.htm	Edgar Link	pending
vyne-20240930xexx321.htm	Edgar Link	pending
vyne-20240930xexx322.htm	Edgar Link	pending
vyne-20240930_def.xml	Edgar Link	unprocessable
vyne-20240930_lab.xml	Edgar Link	unprocessable
vyne-20240930_pre.xml	Edgar Link	unprocessable
vyne-20240930_htm.xml	Edgar Link	completed
vyne-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VYNE
VYNE Therapeutics Inc. Stock $vyne

2024 Q4 Form 10-Q Financial Statement

#000162828024046244 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE VYNE Therapeutics Inc. Stock $vyne

2024 Q4 Form 10-Q Financial Statement

#000162828024046244 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE
VYNE Therapeutics Inc. Stock $vyne